Evidence map›Paper›PMID 34581723›Full record

ArticleThe Journal of cell biology2021

LPHN2 inhibits vascular permeability by differential control of endothelial cell adhesion.

Chiara Camillo, Nicola Facchinello, Giulia Villari, Giulia Mana, Noemi Gioelli, Chiara Sandri, Matteo Astone, Dora Tortarolo, Fabiana Clapero, Dafne Gays and 6 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  4. EndothelialThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Divergent Functions of Rap1A and Rap1B in Endothelial Biology and Disease.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Chiara Camillo *Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.
Nicola Facchinello *Laboratory of Angiogenesis and Cancer Metabolism, Department of Biology, University of Padova, Padova, Italy.ORCID 0000-0003-4898-4064
Giulia Villari *Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-4811-3990
Giulia ManaCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-8931-0739
Noemi GioelliCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-4982-8410
Chiara SandriCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.
Matteo AstoneLaboratory of Angiogenesis and Cancer Metabolism, Department of Biology, University of Padova, Padova, Italy.ORCID 0000-0003-3294-9942
Dora TortaroloCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.
Fabiana ClaperoCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-4070-2942
Dafne GaysDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.ORCID 0000-0002-1338-9583
Roxana E OberkerschLaboratory of Angiogenesis and Cancer Metabolism, Department of Biology, University of Padova, Padova, Italy.
Marco AreseCandiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-7384-9406
Luca TamagnoneInstitute of Histology and Embryology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.ORCID 0000-0002-2884-7946
Donatella Valdembri *Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0003-4590-417X
Massimo M Santoro *Laboratory of Angiogenesis and Cancer Metabolism, Department of Biology, University of Padova, Padova, Italy.ORCID 0000-0003-4605-5085
Guido Serini *Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy.ORCID 0000-0002-3502-8367
Candiolo Cancer Institute · ITUniversity of Padua · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Turin · IT

Funding

European Research Council 647057 - rEnDOxTelethon GGP09175
6 · The paper itself

Abstract

Dynamic modulation of endothelial cell-to-cell and cell-to-extracellular matrix (ECM) adhesion is essential for blood vessel patterning and functioning. Yet the molecular mechanisms involved in this process have not been completely deciphered. We identify the adhesion G protein-coupled receptor (ADGR) Latrophilin 2 (LPHN2) as a novel determinant of endothelial cell (EC) adhesion and barrier function. In cultured ECs, endogenous LPHN2 localizes at ECM contacts, signals through cAMP/Rap1, and inhibits focal adhesion (FA) formation and nuclear localization of YAP/TAZ transcriptional regulators, while promoting tight junction (TJ) assembly. ECs also express an endogenous LPHN2 ligand, fibronectin leucine-rich transmembrane 2 (FLRT2), that prevents ECM-elicited EC behaviors in an LPHN2-dependent manner. Vascular ECs of lphn2a knock-out zebrafish embryos become abnormally stretched, display a hyperactive YAP/TAZ pathway, and lack proper intercellular TJs. Consistently, blood vessels are hyperpermeable, and intravascularly injected cancer cells extravasate more easily in lphn2a null animals. Thus, LPHN2 ligands, such as FLRT2, may be therapeutically exploited to interfere with cancer metastatic dissemination.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAnimals, Genetically ModifiedCapillary PermeabilityCell AdhesionCell LineCell NucleusChlorocebus aethiopsCOS CellsEndothelium, VascularExtracellular MatrixHEK293 CellsHumansHuman Umbilical Vein Endothelial CellsReceptors, G-Protein-CoupledSignal TransductionAdaptor Proteins, Signal TransducingADGRL2 protein, humanReceptors, G-Protein-CoupledTrans-Activators

Identifiers

PMID34581723
PMCPMC8480966
OpenAlexW3202570135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.